Merck KGaA (OTCMKTS:MKGAF) Sets New 1-Year High at $117.14

Merck KGaA (OTCMKTS:MKGAF) shares reached a new 52-week high during trading on Monday . The stock traded as high as $117.14 and last traded at $117.14, with a volume of 12 shares. The stock had previously closed at $116.90.

Separately, ValuEngine downgraded Merck KGaA from a “sell” rating to a “strong sell” rating in a report on Saturday, October 5th.

The firm has a fifty day simple moving average of $111.75 and a 200 day simple moving average of $106.76. The company has a market capitalization of $14.99 billion, a PE ratio of 20.45 and a beta of 0.72. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.68 and a current ratio of 0.94.

About Merck KGaA (OTCMKTS:MKGAF)

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Further Reading: Insider Trading – What You Need to Know

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.